Related Experiment Videos
Montelukast in 2- to 5-year-old children with asthma
1Department of Allergy and Immunology, Children's Hospital of Pittsburgh, 3705 Fifth Ave., 4B 320, Pittsburgh, PA 15213, USA. skonerd@chplink.chp.edu
Insights
A 4-mg daily dose of montelukast chewable tablets was determined to be safe and effective for children aged 2-5 years. This pediatric dosage was established using pharmacokinetic methods, ensuring optimal asthma treatment for young children.
Area of Science:
- Pharmacology
- Pediatric Medicine
- Respiratory Medicine
Background:
- Montelukast is a widely used medication for managing asthma in children.
- Previous studies established an appropriate dosage for older children (6-14 years).
- Dosing for younger children (2-5 years) required specific pharmacokinetic evaluation.
Purpose of the Study:
- To determine the optimal pediatric dose of montelukast for children aged 2-5 years.
- To establish a safe and effective once-daily dosage regimen for this age group.
- To leverage pharmacokinetic data for precise dose selection.
Main Methods:
- Utilized a pharmacokinetic approach for dose determination.
- Applied methods previously used for selecting the 5-mg dose in older children.
- Conducted clinical evaluation of the selected dose in the target pediatric population.
Main Results:
- A once-daily 4-mg chewable tablet of montelukast was identified as the appropriate dose.
- This dosage was subsequently confirmed as safe and effective in children aged 2-5 years.
- The pharmacokinetic approach proved effective for pediatric dose selection.
Conclusions:
- The 4-mg daily dose of montelukast is recommended for asthmatic children aged 2-5 years.
- Pharmacokinetic modeling is a valuable tool for pediatric drug dosage.
- Montelukast provides a safe and effective treatment option for young children with asthma.
Abstract:
Pediatric dose selection for montelukast in 2-5-year-old children was based on a pharmacokinetic approach that was also used in previously selecting a once-daily 5-mg chewable tablet for asthmatic children 6-14 years of age. A 4-mg chewable tablet administered once daily was determined to be the correct dose and was subsequently found to be safe and effective in asthmatic children 2-5 years of age.